# Cumberland Pharmaceuticals Inc.

**CPIX**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001087294

**D**

**fourth fifth of 369 graded peers in healthcare**

rank 265 of 369; percentile 71.7; sampling error 2.5 points; lower is stronger

A B C D E

**D, the sloth**



| Scoreboard | |
|---|---|
| **Profitability** | C<br>percentile 43.1 |
| **Solvency** | C/D<br>percentile 58.4 |
| **Growth and financing** | D<br>percentile 66.8 |
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $76.8M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress, fortress balance sheet |
| **Inputs computable** | 10 of 14 |
| **Graded from** | filings received through Mar 9, 2026<br>246 days before the rescan; latest periodic filing 10-Q received Aug 7, 2026 |
| **Last close** | $5.47<br>2026-11-09; market equity $82.0M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 9, 2026*

Cumberland Pharmaceuticals Inc. ("Cumberland," the "Company," or as used in the context of "we," "us" or "our"), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. We are dedicated to our mission of working together to provide unique products that improve the quality of patient care. Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by relatively small, targeted sales forces.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 43.1** | | | | | | |
| Gross profitability | 49.3% | 32.3% | | 24.2 | 365 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (10.2%) | (6.6%) | 40.7 | 800 | 2025-12-31 |
| Gross margin stability, five years | 3.9 pts | 2.8 pts | 64.3 | 242 | 2025-12-31 |
| **Solvency, sleeve percentile 58.4** | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | (0.86) | (0.35) | 40.5 | 745 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | (5.63x) | (4.51x) | 45.5 | 78 | 2025-12-31 |
| Current ratio | 1.01x | 2.95x | 89.3 | 826 | 2025-12-31 |
| **Growth and financing, sleeve percentile 66.8** | | | | | |
| Revenue growth, three-year compound | 2.0% | 10.1% | 67.1 | 411 | 2025-12-31 |
| Free cash flow growth, three-year compound | (16.7%) | 11.0% | 88.3 | 95 | 2025-12-31 |
| Reinvestment rate | not computable | 37.1% | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | |
| Asset growth, three years | (6.1%) | 2.2% | 64.4 | 694 | 2025-12-31 |
| Net share issuance, one year | 7.1% | 2.5% | 47.5 | 629 | 2026-03-04 |

## Among 369 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 260 | Regeneron Pharmaceuticals, Inc. (REGN) | 70.4 | D | |
| 261 | uniQure N.V. (QURE) | 70.7 | D | fortress balance sheet |
| 262 | Pennant Group, Inc. (PNTG) | 70.9 | D | |
| 263 | Bausch & Lomb Corp. (BLCO) | 71.2 | D | |
| 264 | Bausch Health Companies Inc. (BHC) | 71.5 | D | |
| 265 | Cumberland Pharmaceuticals Inc. (CPIX) | 71.7 | D | |
| 266 | 3M Co. (MMM) | 72.0 | D | |
| 267 | Elanco Animal Health Inc. (ELAN) | 72.3 | D | |
| 268 | Rockwell Medical, Inc. (RMTI) | 72.6 | D | |
| 269 | Butterfly Network, Inc. (BFLY) | 72.8 | D | |
| 270 | ICU Medical Inc/De (ICUI) | 73.1 | D | |

## What the price implies

*at the 2026-11-09 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 231.8% | (1.9%) | 97 |
| Distance from 52-week high | (40.1%) | (27.5%) | 36 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | 6.0% | (1.0%) | 86 |
| Book value to price | 0.22 | 0.27 | 43 |
| Sales to price | 0.55 | 0.29 | 69 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Composite equity issuance, five years | (23.3%) | 20.8% | 6 |
| Relative strength against the sector, log excess return | 1.03 | (0.19) | 97 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | pass |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $3.9M |
| Operating cash flow, four quarters | $745,969 |
| Months of runway | not finite |
| Days since last periodic filing | 95 (10-Q received Aug 7, 2026) |
| Median daily dollar volume, 63 sessions | $405,725 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $44.5M | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $6.7M | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 3 | assets | us-gaap:Assets | $76.8M | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 4 | net income | us-gaap:NetIncomeLoss | -$2.8M | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $4.9M | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 6 | assets | us-gaap:Assets | $75.6M | 2024-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 7 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $37.9M | 2024-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 8 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $6.6M | 2024-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 9 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $39.6M | 2023-12-31 | 2025-03-07 | 10-K | 25-011366 |
| 10 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $6.1M | 2023-12-31 | 2025-03-07 | 10-K | 25-011366 |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $42.0M | 2022-12-31 | 2024-03-13 | 10-K | 24-010725 |
| 12 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $9.1M | 2022-12-31 | 2024-03-13 | 10-K | 24-010725 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $35.0M | 2021-12-31 | 2023-03-13 | 10-K | 23-007727 |
| 14 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $8.8M | 2021-12-31 | 2023-03-13 | 10-K | 23-007727 |
| 15 | current assets | us-gaap:AssetsCurrent | $37.1M | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $36.7M | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$26.8M | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | -$2.8M | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 19 | book equity | us-gaap:StockholdersEquity | $24.9M | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 20 | liabilities | us-gaap:Liabilities | $52.3M | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 21 | interest expense | us-gaap:InterestExpense | $495,990 | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 22 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $97,903 | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$612,186 | 2024-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 24 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $66,461 | 2024-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $6.1M | 2023-12-31 | 2025-03-07 | 10-K | 25-011366 |
| 26 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $281,268 | 2023-12-31 | 2025-03-07 | 10-K | 25-011366 |
| 27 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $8.5M | 2022-12-31 | 2024-03-13 | 10-K | 24-010725 |
| 28 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $102,148 | 2022-12-31 | 2024-03-13 | 10-K | 24-010725 |
| 29 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $4.1M | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 30 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$2.8M | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 31 | income tax | us-gaap:IncomeTaxExpenseBenefit | $40,256 | 2025-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 32 | current assets | us-gaap:AssetsCurrent | $36.5M | 2024-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 33 | current liabilities | us-gaap:LiabilitiesCurrent | $31.6M | 2024-12-31 | 2026-03-09 | 10-K | 26-000020 |
| 34 | assets | us-gaap:Assets | $81.8M | 2023-12-31 | 2025-03-07 | 10-K | 25-011366 |
| 35 | assets | us-gaap:Assets | $92.9M | 2022-12-31 | 2024-03-13 | 10-K | 24-010725 |
| 36 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 14,956,627 | 2026-03-04 | 2026-03-09 | 10-K | 26-000020 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 13,968,394 | 2025-03-04 | 2025-03-07 | 10-K | 25-011366 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.